Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Otenabant. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 known ✓ | P21554 | 20/20 | 1.00 |
| ▸ | CNR2 | P34972 | 15/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Otenabant SCHEMBL3932007 | 0.99 | CNR1 (0.98) | CNR1CNR2KCNH2 | |
| SCHEMBL5235768 | 0.94 | CNR1 (0.88) | CNR1CNR2 | |
| SCHEMBL1315332 | 0.93 | CNR1 (0.86) | CNR1CNR2KCNH2 | |
| SCHEMBL8012474 | 0.92 | CNR1 (0.85) | CNR1CNR2KCNH2 | |
| SCHEMBL5233761 | 0.92 | CNR1 (0.85) | CNR1CNR2KCNH2 | |
| SCHEMBL5240651 | 0.91 | CNR1 (0.84) | CNR1CNR2KCNH2 | |
| SCHEMBL30944012 | 0.90 | CNR1 (0.82) | CNR1CNR2 | |
| SCHEMBL30944092 | 0.89 | CNR1 (0.80) | CNR1CNR2 | |
| SCHEMBL5239445 | 0.89 | CNR1 (0.80) | CNR1CNR2KCNH2 | |
| SCHEMBL5238605 | 0.88 | CNR1 (0.79) | CNR1CNR2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12544366-B2 | Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2026-02-10 | — | — | US | claimed |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES INC (US) | 2025-11-27 | — | — | US | claimed |
| EP-4618980-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | Freedom Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | claimed |
| US-20250288565-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-09-18 | — | — | US | claimed |
| EP-4525836-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | Hadasit Medical Research Services&Development Ltd. (IL) | 2025-03-26 | — | — | EP | claimed |
| EP-4486336-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | Adarx Pharmaceuticals, Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | ANEBULO PHARMACEUTICALS, INC. | 2024-12-12 | — | — | US | claimed |
| WO-2024107445-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | FREEDOM BIOSCIENCES, INC. (US) | 2024-05-23 | — | — | WO | claimed |
| WO-2023223323-A1 | COMBINATION OF ENDOCANNABINOID AND MTOR INHIBITORS IN THE TREATMENT OF NEUROENDOCRINE NEOPLASMS | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2023-11-23 | — | — | WO | claimed |
| WO-2023168296-A2 | CB1 LIGAND CONJUGATED COMPOUNDS AND USES THEREOF | ADARX PHARMACEUTICALS, INC. (US) | 2023-09-07 | — | — | WO | claimed |
| CN-1708499-A | Purine compounds and their use as cannabinoid receptor ligands | PFIZER (US) | 2005-12-14 | — | — | CN | claimed |
| EP-1558615-A1 | PURINE COMPOUNDS AND USE THEREOF AS CANNABINOID RECEPTOR LIGANDS | Pfizer Products Inc. (US) | 2005-08-03 | — | — | EP | claimed |
| WO-2005018645-A1 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | claimed |
| US-20050043327-A1 | Pharmaceutical composition for the prevention and treatment of addiction in a mammal | PFIZER INC | 2005-02-24 | — | — | US | claimed |
| WO-2004098641-A2 | A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF OBESITY OR TO FACILITATE OR PROMOTE WEIGHT LOSS | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| WO-2004098580-A2 | A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF NICOTINE ADDICTION IN A MAMMAL | PFIZER PRODUCTS INC. (US) | 2004-11-18 | — | — | WO | claimed |
| US-20040224963-A1 | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040224962-A1 | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss | PFIZER INC | 2004-11-11 | — | — | US | claimed |
| US-20040092520-A1 | Purine compounds and uses thereof | PFIZER INC. | 2004-05-13 | — | — | US | claimed |
| WO-2004037823-A1 | PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2004-05-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408059-A1 | METHOD OF TREATING ADDICTION | CNR2, CNR1, OPRM1 | CNR1 2/4885CNR2 1/4885KCNH2 2952/4885 |
| US-20250360137-A1 | ENHANCEMENT OF THE EFFICACY OF SEROTONERGIC PSYCHEDELIC DRUGS IN THE TREATMENT OR PREVENTION OF CERTAIN NEUROPSYCHIATRIC DISORDERS THROUGH INHIBITION OF TYPE-9 PHOSPHODIESTERASES | PDE9A, PDE3A, PDE2A | CNR1 221/4885CNR2 204/4885KCNH2 2350/4885 |
| US-12544366-B2 | Combination of endocannabinoid and mTOR inhibitors in the treatment of neuroendocrine neoplasms | RICTOR, MTOR, RPTOR | CNR1 4/4885CNR2 5/4885KCNH2 4688/4885 |
| US-20040092520-A1 | Purine compounds and uses thereof | CNR1, CNR2, P2RY1 | CNR1 1/4885CNR2 2/4885KCNH2 3016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.